ColoSeq Tumor Panel

single page view

General Information

Lab Name
ColoSeq Tumor Panel
Lab Code
CSQTP
Epic Ordering
Order using "UW Genetics and Solid Tumor Test Request"

Place a separate order to draw the paired blood sample.

See tip sheet for more information (internal link).

Description

ColoSeq Paired Tumor-Germline Panel is designed to resolve unexplained mismatch repair deficiency by performing targeted tumor sequencing for somatic mismatch repair (MMR) mutations which have been reported in cancers with IHC loss of MMR protein(s) and normal (negative) germline MMR gene testing. ColoSeq™ Tumor Panel includes both a comprehensive pan-cancer germline analysis of 91 genes associated with hereditary cancer syndromes AND a targeted tumor assessment of select somatic and constitutionally mosaic somatic mutations to aid in the evaluation of mismatch repair deficiency. The tumor analysis includes microsatellite instability, detection of loss of heterozygosity and BRAF V600E mutation.

ColoSeq™ Tumor Panel resolves unexplained mismatch repair deficiency in more than 90% of patients who have mismatch repair deficient tumors and negative germline testing. All exons and flanking intronic sequences are analyzed for all panel genes. Complete promoter and intronic sequencing of the mismatch repair genes, as well as BRCA1/2, is performed, and non-coding variants of uncertain significance are assessed with RNA analysis when certain criteria are met. Select patients may be offered long range sequencing. Many patients undergoing paired tumor-germline testing have already undergone a lot of testing, and these assays are intended to provide conclusive results whenever possible.

ColoSeq™ Tumor assay is not intended to evaluate for somatic mutations for purposes of cancer treatment. Analysis for these tests is limited to select somatic and constitutional mosaic mutations to aid in the diagnosis of genetic and/or hereditary conditions and not all somatic mutations detected are reported. 

ColoSeq™ Tumor Panel uses next-generation sequencing to detect most mutations in AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDK12, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, CTNNB1, DDX41, DICER1, EGFR, EPCAM, ETV6, FANCM, FH, FLCN, GATA2, GEN1, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RINT1, RNF43, RPS20, RSPO3, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SUFU, STK11, TMEM127, TP53, TSC1, TSC2, VHL, and WT1.


Next-generation sequencing is performed on an Illumina instrument to detect single nucleotide variants, insertions, deletions, gene amplifications, and selected translocations.

NOTE: A germline sample is required if germline BROCA or ColoSeq ™ testing was not performed previously at the University of Washington. The germline sample is used to evaluate for the presence of the apparently somatic mutations detected in the tumor, including the identification of constitutional mosaicism. Approximately 7% of patients with prior negative germline testing are found to have a previously undetected pathogenic germline variant or constitutional mosaic mutation in one of the MMR genes.

For an overview of available germline and paired tumor-germline testing for hereditary cancer syndromes, please see: Hereditary Cancer Test Menu: Germline and Paired Tumor-Germline guideline.

ColoSeq Polyposis [CSQP] is available for the evaluation of unexplained polyposis.

ColoSeq Tumor Single Gene [CSQTS] is also available for the analysis of single gene(s) from the ColoSeq™ Tumor Panel.

ColoSeq™ Panel Genes

Gene

Function/Pathway

Heterozygote Cancer Risk*

Associated disease/syndrome

References

ALK

MYC signaling Neuroblastoma

Cowden-like

18724359, 28674118

AKT1

AKT signaling Breast, Thyroid

Cowden-like

23246288

APC

WNT signaling Colon

Familial adenomatous polyposis

20301519

ATM

Double stranded break repair Breast, Pancreatic

Ataxia telangiectasia (recessive)

16832357, 19781682, 22585167

ATR

Double stranded break repair Oropharyngeal

Seckel (recessive)

22341969

AXIN2

WNT signaling Colon

Colon cancer, oligodontia

15042511

BAP1

BRCA1-associated protein complex Uveal Melanoma, Mesothelioma

BAP1 Tumor predisposition syndrome

21874000, 21874003

BARD1

BRCA1-associated protein complex Breast, Ovarian

Hereditary breast cancer

21344236

BMPR1A

TGF-beta signaling Colon

Juvenile Polyposis

20301642

BRAF

Serine/Threonine protein kinase Typically somatic or mosaic only

Typically somatic only, association with MLH1 promoter hypermethylation in colon cancer and Cardiofaciocutaneous syndrome when mosaic

20301365

BRCA1

BRCA1-associated protein complex Breast, Ovarian

Hereditary breast and ovarian cancer

22006311,2270482,7545954

BRCA2

Fanconi/BRCA Breast, Ovarian

Hereditary breast and ovarian cancer, Fanconi anemia FA-D1 (recessive)

22006311,8524414

BRIP1

Fanconi/BRCA Breast, Ovarian

Fanconi anemia FA-J (recessive)

22006311,17033622,21964575

CDH1

Cell adhesion Breast, Gastric

Hereditary diffuse gastric cancer

20301318

CDK4

Cell cycle Melanoma

Familial melanoma

19585149

CDK12

MAP kinase regulation Breast, Ovarian

Typically somatic only; Hereditary breast and ovarian cancer

24554720,29906450,24240700

CDKN1B

Cyclin-dependent kinase inhibitor 1B Parathyroid, Pituitary

Multiple endocrine neoplasia, type IV

37733893

CDKN2A

Cell cycle Pancreatic, Melanoma

Familial melanoma and pancreatic cancer

19585149

CEBPA

Tumor suppressor Leukemia

Familial AML

35178345

CHEK2

Double stranded break repair Breast Hereditary breast cancer 11967536

CTNNA1

Beta-catenin, e-cadherin complex Gastric

Hereditary diffuse gastric cancer

23208944

CTNNB1

WNT signaling Typically somatic only

Colon cancer, endometrial cancer, desmoid tumors, colon adenomas

33115416, 37048063

DDX41

Splicing regulation Leukemia, MDS

Familial MDS, AML

26712909,34723452

DICER1

Tumor suppressor Wilms tumor, Pleuropulmonary blastoma

DICER1 syndrome

29343557,28960912,23625684

EGFR

Epidermal growth factor receptor Lung

Familial lung cancer

37274482

EPCAM

Deletions inactivate MSH2, mismatch repair Colon, Ovarian, Endometrial

Lynch syndrome

23938213

ETV6

Transcription factor in hemopoietic regulation Leukemia, MDS

Familial thrombocytopenia, MDS, acute leukemia

28555414

FANCM

Fanconi/BRCA Breast

Fanconi anemia (recessive)

25288723

FH

Tumor suppressor Renal

Hereditary leiomyomatosis and renal cell cancer

25018647,11865300,25004247

FLCN

Tumor suppressor Renal

Birt-Hogg-Dube syndrome. Primary spontaneous pneumothorax.

12204536, 19659657

GATA2

Transcription factor in hemopoietic regulation Leukemia, MDS

Familial leukemia, MDS, immunodeficiency

38660832, 36455197

GEN1

Double stranded break repair Breast

Hereditary breast cancer

20512659

GREM1

BMP antagonist Colon

Hereditary mixed polyposis syndrome

22561515

HOXB13

Sequence-specific transcription factor which binds preferentially to methylated DNA Prostate

Familial prostate cancer

36446039, 34799695, 34059701

KIF1B

Tumor suppressor Neuroblastoma

Hereditary neuroblastoma

18334619, 24469107, 30859632

KIT

Proto-oncogene which encodes a tyrosine-protein kinase that acts as a cell-surface receptor for cytokine KITLG/SCF Gastrointestinal stromal tumors (GIST), Acute myelogenous leukemia (AML)

Hereditary GIST and AML

36351335, 35821557

LZTR1

RAS ubiquitination/MAPK signaling Schwannomatosis

Schwannomatosis, Noonan syndrome

24362817, 25335490

MAX

MYC signaling Pheochromocytoma, Paraganglioma

Hereditary pheochromocytoma and paraganglioma

21685915, 22452945

MBD4

Mismatch DNA repair Uveal Melanoma, myelodysplastic disease, colon polyposis

Polyposis, multi-organ tumor predisposition (recessive)

32239153, 35460607, 30049810

MEN1

Gene expression regulation Endocrine

Multiple endocrine neoplasia type 1

9215689

MET

Tyrosine Kinase receptor Kidney, Squamous cell carcinomas

Hereditary papillary renal cell carcinoma

11551094,9140397,27330189

MITF

Melanocyte inducing transcription factor Kidney, Melanoma

MITF-related melanoma and renal cell carcinoma predisposition

24290354,22012259

MLH1

Mismatch DNA repair Colon, Ovarian, Endometrial

Lynch syndrome

20301390

MLH3

Mismatch DNA repair Polyposis (recessive)

unknown

30573798

MSH2

Mismatch DNA repair Colon, Ovarian, Endometrial

Lynch syndrome

20301390

MSH3

Mismatch DNA repair Polyposis

Familial adenomatous polyposis 4 (recessive)

27476653, 35675019, 38243056

MSH6

Mismatch DNA repair Colon, Endometrial

Lynch syndrome

20301390

MUTYH

DNA repair Colon

MUTYH-associated polyposis (recessive)

20301519, 21952991

NBN

Double stranded break repair Breast

Nijmegen breakage syndrome (recessive)

15185344,9590180

NF1

MAPK signaling Optic Glioma, Peripheral Nerve Sheath, Breast

Neurofibromatosis

2114220, 23165953, 20301288

NF2

Cellular regulation Acoustic neuromas, Vestibular Schwannomas

Neurofibromatosis

20301380

NTHL1

Base excision repair Colon polyps, Endometrial, Breast, Pancreatic

Hereditary cancer with colon polyposis (recessive)

25938944, 26431160

PALB2

Fanconi/BRCA Breast, Pancreatic

Fanconi anemia FA-N (recessive)

17200668,17200671,25099575

PDGFRA

Protein tyrosine kinase GIST, often somatic

Familial, sporadic GIST

25975287, 23036227

PHOX2B

Tumor suppressor Neuroblastoma

Hereditary neuroblastoma

17637745,28674118

PIK3CA

AKT signaling Breast, Thyroid

Cowden-like

22729224, 23246288

PMS2

Mismatch DNA repair Colon, Endometrial

Lynch syndrome

20301390

POLD1

DNA Polymerase Colon, Endometrial

Familial polyposis, colorectal cancer

23263490, 23770608

POLE

DNA Polymerase Colon

Familial polyposis, colorectal cancer

23263490

POT1

Telomere maintenance Melanoma, CLL, Sarcoma, Glioma, Colon, Thyroid, Breast

Multi-organ tumor predisposition

23502782, 24686849, 28853721, 37140166

PRKAR1A

cAMP signaling Endocrine Carney complex (recessive) 4010501

PTCH1

Hedgehog Basal cell carcinoma, PNET

Nevoid basal cell-carcinoma syndrome

8681379, 8658145, 20301330

PTEN

PI3K/MAPK Signaling Breast

Cowden syndrome

20301661

RAD51B

Double stranded break repair Unknown Hereditary breast and ovarian cancer 24139550

RAD51C

Fanconi/BRCA Ovarian, Breast Hereditary breast and ovarian cancer 22006311,22538716

RAD51D

Fanconi/BRCA Ovarian, Breast Fanconi anemia FA-O (recessive) 21822267,22415235

RB1

Tumor suppressor Retinoblastoma, Sarcoma, Melanoma Fanconi anemia (recessive) 25621664,22355046,20301625

RECQL

DNA repair Breast Hereditary retinoblastoma 25915596

RET

Receptor Tyrosine Kinase Endocrine Hereditary breast cancer 20301434

RINT1

DNA checkpoint regulation Breast, Colon Multiple endocrine neoplasia type 2 25050558

RNF43

WNT signaling Colon

Sessile Serrated Polyposis

27329244, 27081527

RPS20

Ribosomal protein Colon

unknown

24941021

RSPO3

WNT signaling Typically somatic only Colon cancer 29127379, 37048063

RUNX1

Hematopoietic stem cell regulation (transcription factor) myelodysplastic syndrome and acute myeloid leukemia

RUNX1-familial platelet disorder

21148331

SDHA

Succinate dehydrogenase complex Pheochromocytoma, Paraganglioma

Hereditary paraganglioma-pheochromocytoma

20484225, 21752896

SDHAF2

Succinate dehydrogenase complex Pheochromocytoma, Paraganglioma

Hereditary paraganglioma-pheochromocytoma

20301715

SDHB

Succinate dehydrogenase complex Pheochromocytoma, Paraganglioma

Hereditary paraganglioma-pheochromocytoma

11404820

SDHC

Succinate dehydrogenase complex Pheochromocytoma, Paraganglioma

Hereditary paraganglioma-pheochromocytoma

11062460

SDHD

Succinate dehydrogenase complex Pheochromocytoma, Paraganglioma

Hereditary paraganglioma-pheochromocytoma

10657297

SMAD4

TGF-beta signaling Colon

Juvenile Polyposis

20301642

SMARCA4

SWI/SNF complex Ovarian Ovarian
Hereditary small cell carcinoma of the ovary, hypercalcemic
24658002

SMARCB1

ATP-dependent SWI/SNF chromatin remodeling complex Schwannoma, Rhabdoid tumors, Meningioma Schwannomatosis; Rhabdoid tumor predisposition syndrome type 1 28109176, 29706634

SMARCE1

DNA repair and replication Spinal meningioma Familial spinal meningioma 23377182

STK11

Tumor suppressor Breast, Colon, Pancreatic, Gastric, Hamartomas Peutz-Jeghers syndrome 20301443

SUFU

Hedgehog Signaling Basal cell carcinoma, Medulloblastoma, Meningioma, Gonadal tumors Nevoid basal cell-carcinoma syndrome (Gorlin syndrome) 19533801, 35768194

TMEM127

Tumor suppressor Pheochromocytoma, Paraganglioma Hereditary paraganglioma-pheochromocytoma 20301715

TP53

Cell growth Breast, Ovarian

Li-Fraumeni syndrome

22006311, 20301488

TSC1

Cell growth Hamartomas

Tuberous sclerosis complex

10227394,9924605,17287951

TSC2

Cell growth Hamartomas

Tuberous sclerosis complex

8825048,9829910

VHL

p53 regulation Kidney, Neuroendocrine

von Hippel-Lindau syndrome

20301636

WT1

WT1 transcription factor Wilms tumor

Wilms tumor

15150775

For previous versions of ColoSeq™ - Lynch and Polyposis Panel, see Previous Versions, COSEQ.

References
  • Pritchard CC, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012, 14:357-66. 22658618
  • Walsh T, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010, 107:12629-33. 20616022
  • Nord AS, Lee M, King MC, and Walsh T. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics 2011, 12:184. 21486468
  • Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010, 11:31-46. 19997069
  • Rhees J, Arnold M, and Boland CR. Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population. Fam Cancer 2014, 13:219-25. 24114314
  • Mensenkamp AR, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 2014, 146:643-646.e8. 24333619
  • Haraldsdottir S, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 2014, 147:1308-1316.e1. 25194673
  • Salipante SJ, Scroggins SM, Hampel HL, Turner EH, and Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem 2014, 60:1192-9. 24987110
Forms & Requisitions

Requisition Form and Ordering Instructions:

1. Fill out a Genetics Requisition Form

Providers with access to the UW implementation of Epic (i.e., FHCC, HMC, SCCA, UWMC, UWNW) may order this test using the order "UW Genetics and Solid Tumor Test Request." See tip sheet for more information (internal link).

2. Check "ColoSeq™ – Tumor Panel" or "ColoSeq™ - Tumor Single Gene" as desired.

3. For ColoSeq™ - Tumor Single Gene, specify gene in space provided.

4. Unless prior germline testing was performed at University of Washington, also select: "Normal Control (blood)."

5. Select the appropriate “Specimen Submitted."

6. Submit test requisition with peripheral blood sample and a copy of the tumor pathology report.

NOTE: Tumor specimen will be requested directly, by UW Laboratory Medicine and Pathology, from the originating pathology department, and therefore, in most cases, it is not necessary to submit tumor block or slides.

Synonyms
AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, biallelic somatic, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDK4, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, CTNNB1, DDX41, DICER1, double somatic, EGFR, EPCAM, ETV6, FANCM, FH, FLCN, GATA2, GEN1, GREM1, HOXB13, KIF1B, KIT, Lynch syndrome, LZTR1, MAX, MBD4, MEN1, MET, mismatch repair deficiency, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RINT1, RNF43, RPS20, RSPO3, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WT1
Components

Interpretation

Method

Next-generation sequencing.

This assay sequences all exons, flanking intronic splice site sequences, and select promoter regions of AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, BRAF, BRCA1*, BRCA2*, BRIP1, CDH1, CDK4, CDK12, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, CTNNB1, DDX41, DICER1, EGFR, EPCAM, ETV6, FANCM, FH, FLCN, GATA2, GEN1, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1*, MLH3, MSH2*, MSH3, MSH6*, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2*, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RNF43, RPS20, RSPO3, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SUFU, STK11, TMEM127, TP53, TSC1, TSC2, VHL, and WT1.
Gene introns are also sequenced for genes indicated above with an asterisk (*).

Sequences are aligned to the human genome reference (HG38). Test performed by targeted capture for listed genes followed by next-generation sequencing with Illumina technology. This test was developed and its performance characteristics determined by the University of Washington Department of Laboratory Medicine. It has not been cleared or approved by the US Food and Drug Administration. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

Reference Range
See individual components
Ref. Range Notes

No mutations detected.

References
  • Pritchard CC, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012, 14:357-66. 22658618
  • Walsh T, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010, 107:12629-33. 20616022
  • Nord AS, Lee M, King MC, and Walsh T. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics 2011, 12:184. 21486468
  • Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010, 11:31-46. 19997069
  • Rhees J, Arnold M, and Boland CR. Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population. Fam Cancer 2014, 13:219-25. 24114314
  • Mensenkamp AR, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 2014, 146:643-646.e8. 24333619
  • Haraldsdottir S, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 2014, 147:1308-1316.e1. 25194673
  • Salipante SJ, Scroggins SM, Hampel HL, Turner EH, and Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem 2014, 60:1192-9. 24987110
Guidelines

Ordering & Collection

Specimen Type
Formalin-Fixed Paraffin Embedded Tumor Tissue (FFPE), Purified DNA, Peripheral Blood, cultured cells from skin biopsy, purified DNA from peripheral blood or cultured cells, saliva
Collection

Tumor specimen will be requested directly, by UW Laboratory Medicine, from the originating pathology department. In order to facilitate this, a pathology report should be submitted with the test requisition, blood control and other clinical and billing paperwork.

NOTE: This test requires BOTH tumor tissue and peripheral blood. Only tumor tissue is required if ColoSeq™ testing on peripheral blood has been done previously at UW Lab Medicine.

Tumor Tissue:

Tumor specimen will be requested directly, by UW Laboratory Medicine, from the originating pathology department. In order to facilitate this, a pathology report should be submitted with the test requisition, blood control and other clinical and billing paperwork.

If the tumor specimen is being submitted by the ordering provider, tissue samples (FFPE) either (a) slides, OR (b) tissue block are required.

(a) Instructions for slide specimens: 1 slide at 4-micron thickness stained with hematoxylin-and-eosin AND 20 unstained, non-baked slides at 10-micron thickness (a minimum of 10 unstained slides is acceptable). Unstained slides can be on charged or uncharged slides. Note: Sections should contain as much tumor tissue as possible.

(b) Instructions for tissue block specimen: Provide complete tissue block containing tumor tissue. If there is more than one tissue block, please provide the block that has the greatest amount of tumor tissue. Tissue block will be returned at completion of testing. Ship at room temperature.

NOTE: If germline MMR testing was performed in a different laboratory, a peripheral blood sample should be submitted in addition to tumor tissue.

Germline control sample:

BLOOD:

  • 10 mL whole blood in LAVENDER TOP EDTA tube.
  • Also acceptable: YELLOW TOP ACD tube, purified DNA from peripheral blood or cultured cells.

SALIVA:
Contact laboratory for validated collection kit.

SKIN BIOPSY:

  • Collection and transport: Obtain 2-4 mm punch biopsy of skin sample under sterile conditions and place in transport media (e.g. Alpha-MEM media, RPMI). Transport media can be supplied by the lab; call 206-598-4488 to request. If transport media is not available, the following media are acceptable alternatives if shipping time will not exceed 24 hours: lactated Ringer's solution, viral transport medium, or sterile saline. DO NOT USE formaldehyde, formalin, alcohol, or 5% dextrose, or tissue culture medium buffered with bicarbonate.

CULTURED CELLS:

  • (2) T23 or (1) T75 flask (minimum 1-T25 flask).
Forms & Requisitions

Requisition Form and Ordering Instructions:

1. Fill out a Genetics Requisition Form

Providers with access to the UW implementation of Epic (i.e., FHCC, HMC, SCCA, UWMC, UWNW) may order this test using the order "UW Genetics and Solid Tumor Test Request." See tip sheet for more information (internal link).

2. Check "ColoSeq™ – Tumor Panel" or "ColoSeq™ - Tumor Single Gene" as desired.

3. For ColoSeq™ - Tumor Single Gene, specify gene in space provided.

4. Unless prior germline testing was performed at University of Washington, also select: "Normal Control (blood)."

5. Select the appropriate “Specimen Submitted."

6. Submit test requisition with peripheral blood sample and a copy of the tumor pathology report.

NOTE: Tumor specimen will be requested directly, by UW Laboratory Medicine and Pathology, from the originating pathology department, and therefore, in most cases, it is not necessary to submit tumor block or slides.

Handling Instructions

Attach a copy of the pathology report for the tumor sample being submitted.

Ship specimen at room temperature for overnight delivery.

Blood specimens can be held for up to 7 days before shipping if refrigerated.

Ship specimens to:

UW MEDICAL CENTER

LABORATORY MEDICINE - GENETICS LAB

1959 NE PACIFIC ST, ROOM NW220

SEATTLE, WA 98195-7110

Quantity
requested: Entire sample
minimum: Tissue: 10 unstained slides plus one H&E-stained; slide or extracted DNA: 5 microgram AND 5 mL control peripheral blood (DNAPRP)

Processing

Processing

Blood: Refrigerate whole blood

Unacceptable Conditions: Frozen or clotted specimens

Stability (collection to initiation of testing): Ambient: 5 days; Refrigerated: 7 days; Frozen: Unacceptable

Purified DNA: Refrigerate DNA specimens. Frozen is acceptable.

Performance

LIS Dept Code
Genetics (GEN)
Performing Location(s)
UW-MT Genetics

Attention: Genetics Lab
Clinical lab, Room NW220
University of Washington Medical Center
1959 NE Pacific Street
Seattle, WA 98195

Tel: 206-598–6429 M–F (7:30 AM–4:00 PM)
Fax: 206-616-4584
Lab email: cgateam@uw.edu

Tel (EXOME only): 206-543-0459

Faculty
Jillian Buchan, PhD, FACMG
Runjun Kumar, MD, PhD
Regina Kwon, MD, MPH
Christina Lockwood, PhD, DABCC, DABMGG
Abbye McEwen, MD, PhD
Colin Pritchard, MD, PhD
Vera Paulson, MD, PhD
Eric Konnick, MD, MS
He Fang, PhD

Frequency
Results within 4-6 weeks, once sample arrives in the laboratory.
Available STAT?
No

Billing & Coding

CPT codes
Billing Comments

For additional test/billing information, see following page, CPT codes for Hereditary Cancer Panels (germline and paired).

For pricing information, contact Client Support Services 206-520-4600 or 800-713-5198.

Billing and Insurance Pre-Authorization

We offer insurance pre-authorization services (preauthorization is only done for providers who are external to the UW system).

Email: gpab@uw.edu or call 1-855-320-4869 for more information.

A letter of medical necessity is highly recommended for ColoSeq™ Tumor testing, and a template is available by emailing genelab@uw.edu.

Genetics Preauthorization Form

LOINC
51967-8
Interfaced Order Code
UOW2961